Global Digital Biomarkers Market Size, Share, Trends, and Forecast, 2026-2036 | AI, Wearables, and Decentralized Trials Drive 13.4% CAGR to USD 34.6 Billion

Boost ROI with AI analytics, wearables, strategic partnerships and decentralized trials that enhance data quality, reduce patient burden and accelerate drug development

Dublin, Oct. 05, 2026 (GLOBE NEWSWIRE) -- "Digital Biomarkers Market Size, Share & Trends Analysis - Global Opportunity Analysis & Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering.

The global Digital Biomarkers Market was valued at USD 7.6 billion in 2025 and is projected to increase from an estimated USD 9.8 billion in 2026 to USD 34.6 billion by 2036. The market is expected to register a CAGR of 13.4% during the forecast period, supported by advances in digital health technologies, remote patient monitoring, artificial intelligence (AI), data analytics, decentralized clinical trials, and personalized medicine.

Market expansion is being driven by the rising prevalence of chronic diseases, growing demand for continuous patient monitoring, and broader adoption of connected healthcare platforms. Pharmaceutical and biotechnology companies are integrating digital biomarkers into clinical trials and drug development programs to improve data collection, assess treatment response, support patient stratification, and generate real-world evidence.

Wearable technologies are playing a central role in this growth. Smartwatches, fitness trackers, biosensors, smartphones, implantable devices, and connected medical equipment can collect physiological and behavioral data across clinical and real-world settings. These technologies support disease management, preventive care, early detection, remote monitoring, and personalized healthcare interventions.

Advances in artificial intelligence and machine learning, Internet of Things (IoT), cloud computing, sensor technologies, and healthcare analytics are improving the accuracy and scalability of digital biomarker platforms. AI-powered systems can process large volumes of health data, identify clinically relevant patterns, and support predictive models for disease progression, treatment optimization, and clinical decision-making.

Digital Biomarkers Market Dynamics

The increasing use of digital endpoints in clinical research represents a significant market opportunity. Continuous data collection can enhance trial efficiency, reduce patient burden, strengthen safety and efficacy assessments, and support decentralized clinical trial models. Adoption is also expanding across cardiovascular diseases, neurological disorders, oncology, metabolic disorders, respiratory diseases, and mental health conditions.

Key market challenges include data privacy concerns, regulatory uncertainty, interoperability limitations, validation requirements, and variability in digital health data quality. Industry participants are responding through stronger cybersecurity measures, standardized data platforms, regulatory-compliant development practices, and collaborations among technology companies, healthcare providers, pharmaceutical organizations, and research institutions.

Market Segment Analysis

By biomarker type, the market includes physiological biomarkers, behavioral biomarkers, molecular biomarkers, and digital phenotypes. Physiological biomarkers hold a significant position because of their use in monitoring heart rate, blood pressure, glucose levels, respiratory patterns, and sleep characteristics. Behavioral biomarkers are expected to record strong growth as healthcare organizations increase monitoring of mobility, activity, cognition, sleep behavior, and mental health. Digital phenotypes are also gaining importance as AI and analytics improve the interpretation of combined physiological, behavioral, environmental, and clinical data.

By data source/device type, the market covers wearable devices, smartphones and mobile applications, implantable devices, remote monitoring devices, and other connected devices. Wearable devices represent a leading segment due to growing consumer adoption and increased use in clinical trials, chronic disease management, and preventive care. Smartphones and mobile applications are positioned for continued growth because of their accessibility and ability to support remote and decentralized healthcare models.

By technology, artificial intelligence and machine learning account for a major market share, with applications in predictive analytics, patient stratification, personalized treatment, and disease monitoring. IoT platforms support real-time data transmission and connectivity among medical devices, healthcare systems, and data management platforms. Cloud computing, advanced analytics, and sensor technologies further strengthen the digital health infrastructure required for scalable deployment.

Major applications include clinical trials, disease monitoring, personalized medicine, drug development, remote patient monitoring, and wellness management. Pharmaceutical and biotechnology companies represent the leading end-user segment, while healthcare providers, research organizations, academic institutions, and technology companies are increasing adoption across clinical and commercial settings.

Regional Market Outlook

North America dominates the global digital biomarkers market due to its advanced healthcare infrastructure, strong digital health adoption, established pharmaceutical and technology sectors, and extensive clinical research activity. Europe remains a significant market, supported by healthcare digitalization initiatives, regulatory developments, and expanding research involving digital endpoints.

Asia-Pacific is expected to register strong growth as healthcare infrastructure improves and adoption of smartphones, wearable devices, and remote monitoring solutions increases. China, Japan, South Korea, and India are strengthening their digital healthcare ecosystems amid rising chronic disease prevalence and technology investment. Latin America and the Middle East & Africa also offer emerging opportunities as healthcare access expands and modernization programs accelerate.

Competitive Landscape

Competition is shaped by technology capabilities, platform integration, clinical validation, regulatory expertise, geographic presence, and data analytics performance. Companies are investing in wearable biosensors, mobile applications, cloud-based healthcare platforms, AI-enabled analytics, and decentralized clinical trial solutions. Strategic partnerships, acquisitions, product launches, and collaborations are helping market participants expand clinical applications and accelerate commercialization.

Key companies profiled in the report include Biofourmis, Koneksa Health, Inc., ActiGraph LLC, Medidata Solutions , Inc. ( Dassault Systemes ), Icon Plc , Verily Life Sciences LLC, AliveCor, Inc., Philips N.V., and Empatica Inc.

Key Report Benefits

• Provides market size estimates and long-term growth forecasts through 2036.
• Assesses major drivers, restraints, challenges, and emerging opportunities.
• Identifies high-growth biomarker type, device, technology, application, end-user, and regional segments.
• Evaluates innovation across wearable technologies, AI-based analytics, remote monitoring platforms, and digital clinical trial solutions.
• Benchmarks leading companies by product portfolio, technology capability, strategic activity, and competitive positioning.
• Supports investment planning, partnership evaluation, clinical research strategies, market entry, and digital health implementation.

The report delivers actionable digital biomarkers market intelligence for pharmaceutical companies, biotechnology firms, healthcare providers, technology developers, research organizations, investors, and other stakeholders seeking to evaluate growth opportunities, optimize clinical programs, and strengthen their positions within the global digital health ecosystem.

Key Topics Covered

1. Introduction
1.1. Market Definition
1.2. Scope
1.3. Market Ecosystem
1.4. Currency and Limitations
1.4.1. Currency
1.4.2. Limitations
1.5. Key Stakeholders

2. Research Methodology
2.1. Research Approach
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
2.3.3. Forecast Modeling
2.4. Data Triangulation
2.5. Assumptions

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Increasing Adoption of Wearables & Remote Monitoring
4.2.1.2. Growth in Digital Clinical Trials
4.2.1.3. Rising Demand for Real-world Data (RWD)
4.2.1.4. Expansion of Digital Therapeutics
4.2.2. Restraints
4.2.2.1. Lack of Standardization and Validation
4.2.2.2. Data Privacy & Security Concerns
4.2.2.3. Regulatory Uncertainty
4.2.3. Opportunities
4.2.3.1. Integration with AI & Predictive Analytics
4.2.3.2. Expansion in Chronic Disease Management
4.2.3.3. Growth in Decentralized Clinical Trials
4.2.3.4. Increasing Partnerships Between Pharma & Tech Firms
4.2.4. Challenges
4.2.4.1. Data Interoperability Issues
4.2.4.2. Patient Engagement and Compliance
4.3. Technology Landscape
4.3.1. Wearable Devices & Sensors
4.3.2. Mobile Health (mHealth) Applications
4.3.3. Remote Monitoring Platforms
4.3.4. AI & Data Analytics Platforms
4.3.5. Cloud-based Data Infrastructure
4.4. Digital Biomarkers Ecosystem
4.4.1. Digital Health Companies
4.4.2. Pharmaceutical & Biotechnology Companies
4.4.3. CROs
4.4.4. Healthcare Providers
4.4.5. Patients & Consumers
4.5. Value Chain Analysis
4.5.1. Data Collection (Sensors/Devices)
4.5.2. Data Transmission & Storage
4.5.3. Data Processing & Analytics
4.5.4. Interpretation & Clinical Integration
4.5.5. Outcome Measurement
4.6. Regulatory Landscape
4.6.1. FDA Digital Health Guidelines
4.6.2. EMA & Global Frameworks
4.6.3. Data Privacy Regulations (HIPAA, GDPR)
4.7. Industry Trends
4.7.1. Rise of Decentralized Clinical Trials
4.7.2. Growth of AI-driven Biomarker Discovery
4.7.3. Integration with Digital Therapeutics
4.7.4. Increasing Use in Chronic Disease Management
4.8. Cost and Pricing Analysis
4.8.1. Cost by Technology Type
4.8.2. Pricing Models (Subscription, SaaS, Licensing)
4.8.3. ROI in Clinical Trials

5. Digital Biomarkers Market, by Biomarker Type
5.1. Introduction
5.2. Physiological Biomarkers
5.2.1. Heart Rate & Cardiac Metrics
5.2.2. Respiratory Metrics
5.2.3. Activity & Mobility
5.3. Behavioral Biomarkers
5.3.1. Sleep Patterns
5.3.2. Cognitive Function
5.3.3. Digital Interaction Patterns
5.4. Biochemical Digital Biomarkers
5.5. Other Biomarker Types

6. Digital Biomarkers Market, by Data Source / Device Type
6.1. Wearable Devices (Smartwatches, Fitness Bands)
6.2. Smartphones & Mobile Apps
6.3. Implantable Devices
6.4. Remote Monitoring Systems
6.5. Other Devices

7. Digital Biomarkers Market, by Technology
7.1. AI & Machine Learning
7.2. Cloud & Big Data Analytics
7.3. IoT-enabled Platforms
7.4. Sensor Technologies

8. Digital Biomarkers Market, by Application
8.1. Introduction
8.2. Clinical Trials
8.3. Disease Diagnosis
8.4. Remote Patient Monitoring
8.5. Drug Development & R&D
8.6. Digital Therapeutics
8.7. Wellness & Preventive Care

9. Digital Biomarkers Market, by End User
9.1. Pharmaceutical & Biotechnology Companies
9.2. CROs
9.3. Healthcare Providers
9.4. Research Institutes
9.5. Patients / Consumers

10. Digital Biomarkers Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Netherlands
10.3.7. Sweden
10.3.8. Switzerland
10.3.9. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. South Korea
10.4.5. Australia
10.4.6. Singapore
10.4.7. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6. Middle East & Africa
10.6.1. UAE
10.6.2. Saudi Arabia
10.6.3. South Africa
10.6.4. Rest of MEA

11. Competitive Landscape
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Emerging Players
11.5. Market Ranking/Positioning Analysis

12. Company Profiles
Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis
12.1. Apple .
12.2. Alphabet Inc.
12.3. Fitbit ( Alphabet )
12.4. Garmin .
12.5. Empatica Inc.
12.6. ActiGraph LLC
12.7. Biofourmis
12.8. AliveCor Inc.
12.9. Philips Healthcare
12.10. Medtronic plc
12.11. Abbott
12.12. Biogen Inc.
12.13. Roche AG
12.14. Novartis AG
12.15. Sanofi

13. Appendix
13.1. Customization Options
13.2. Related Reports

For more information about this report visit https://www.researchandmarkets.com/r/gpl3sq

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900